Skip to main content Back to Top
Advertisement

11/6/2019

Guanfacine Hydrochloride Tablets

Products Affected - Description

    • Guanfacine hydrochloride oral immediate release tablet, Mylan, 1 mg, bottle, 100 count, NDC 00378-1160-01
    • Guanfacine hydrochloride oral immediate release tablet, Mylan, 2 mg, bottle, 100 count, NDC 00378-1190-01
    • Guanfacine hydrochloride oral immediate release tablet, Teva, 2 mg, bottle, 100 count, NDC 00591-0453-01

Reason for the Shortage

    • Amneal has guanfacine tablets available.
    • Mylan did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.

Available Products

    • Guanfacine hydrochloride oral immediate release tablet, Amneal, 1 mg, bottle, 100 count, NDC 65162-0711-10
    • Guanfacine hydrochloride oral immediate release tablet, Amneal, 2 mg, bottle, 100 count, NDC 65162-0713-10
    • Guanfacine hydrochloride oral immediate release tablet, Teva, 1 mg, bottle, 100 count, NDC 00591-0444-01

Estimated Resupply Dates

    • Teva has guanfacine 2 mg tablets in 100 count bottles on back order and the company cannot estimate a release date.
    • Mylan has guanfacine 1 mg and 2 mg tablets in 100 count bottle on back order and the company estimates a release date of mid-January 2020

Updated

Updated November 6, 2019 by Rachael Freeman, PharmD, BCPS. Created January 4, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins